



October 25-28, 2014 | Pennsylvania Convention Center | Philadelphia, PA

(9117-TC) Sally Frank Memorial Award and Lectureship: The Monocyte Monolayer Assay (MMA) Past and Present and Other Tests That Help Predict An Antibody's Potential Clinical Significance

October 25, 2014 \diamond 2:00 PM - 5:30 PM





Event Faculty List

Event Title:(9117-TC) Sally Frank Memorial Award and Lectureship: The Monocyte Monolayer Assay (MMA)
Past and Present and Other Tests That Help Predict An Antibody's Potential Clinical SignificanceEvent Date:October 25, 2014Event Time:2:00 PM - 5:30 PM

Director/Moderator Debra Bailey, MT(ASCP)SBB debski@mindspring.com Disclosure: No

Award Recipient/Speaker

Donald Branch, BS, MT(ASCP)SBB, PhD Scientist Centre for Innovation, Canadian Blood Services don.branch@utoronto.ca Disclosure: No

Speaker


Gregory Denomme, PhD, FCSMLS(D) Director of Immunohematology & Transfusion Services BloodCenter of Wisconsin Gregory.Denomme@BCW.edu Disclosure: Did not disclose

Speaker


Regina Leger, MSQA, MT(ASCP)SBB, CMQ/OE(ASQ) Research Associate American Red Cross Southern California Region regina.leger@redcross.org Disclosure: No


Speaker


Sandra Nance, MS, MT(ASCP)SBB Sr. Director, IRL, Biomedical Services Operations and Heritage Division American Red Cross Blood Services Sandra.Nance@redcross.org Disclosure: Did not disclose





Canadian Blood Services it's in you to give

























































Correlation of MMA with DAT and AIHA

- MMA distinguished between hemolysing and non-hemolysing patients independent of the degree of red cell sensitization as determined by the DAT when using phagocytosis as readout
- 16/16 patients with a positive DAT (0.5+ to 4+) and clinical evidence of hemolysis showed elevated phagocytic index (PRBC) (>2)
- 6/6 patients with a positive DAT (0.5+ to 4+) without clinical evidence
 of hemolysis did not show an elevated PRBC
- 2/6 patients with a positive DAT following alpha-methyldopa therapy were hemolysing, 4 were not; the MMA correlated 100% with *in vivo* findings
- 7/11 patients with DAT-negative acquired hemolytic anemia showed elevated PRBC index, indicating a possible immune etiology involving extravascular lysis

¢

 3/7 of these MMA positive DAT-negative patients only showed a significantly elevated PRBC when autologous monocytes were used







MMA can distinguish between hemolyzing and non-hemolyzing antibody

MØ PRBC
43
1
15
2
2



MMA useful to study clinical significance of RBC alloantibodies

British Journal of Haematology, 1984. 56, 19-29

In vitro determination of red cell alloantibody significance using an assay of monocyte–macrophage interaction with sensitized erythrocytes DONALD R. BRANCH. MICHAEL T. GALLAGHER, ANGELES P. MISON,


ANITA L. SY SION HIAN AND LAWRENCE D. PETZ Department of Clinical and Experimental Immunology, Division of Medicine, City of Hope National Medical Center, Duarte, California


C

adian Blood Ser it's in you to give


Received 15 March 1983; accepted for publication 24 May 1983

BLOOD.CA WWW.BLOOD.CA WW









Four Critical Points from Study

 Addition of fresh complement and homozygous target cells is important for certain alloantibodies

The percentage of anti-Jka and anti-Fya mediating significant phagocytosis was increased when fresh complement was added during the sensitization procedure and/or red cells homozygous for the antigen in question were used

LOOD.CA WWW.BLOOD.CA WW

Four Critical Points from Study

• Where clinical data was available, the MMA would have predicted hemolysis or no hemolysis prior to transfusion

The *in vivo* clinical significance or lack of significance was documented for nine alloantibodies; five caused hemolysis and four did not. Those causing *in vivo* hemolysis mediated *in vitro* phagocytosis by monocyte-macrophages whereas the antibodies that did not result in hemolysis showed no increased *in vitro* phagocytosis.

BLOOD.CA WWW.BLOOD.CA WW

		in vitro monocyte-macrophage assay with alloantibodies heir in vivo clinical significance or insignificance	having	
Antibody specificity	IAT*	Documented clinical significance or insignificance	Phagocytic index† (PRBC)	
Anti-M	3+	Delayed haemolytic transfusion reaction: ⁵¹ Cr-survival 1-4% at 24 h (Alperin et al. 1983) 5 units of Ge-positive blood transfused: no untoward	44.5.*	
		response	0	
Anti-Ge Anti-Ge	2+ 4+	Newborn with 1 + DAT, no clinical haemolytic disease Haemolytic transfusion reaction: ⁵¹ Cr-survival < 4% at 24 h	1	
Anti-Ce Anti-Vel		Haemotytic transfusion reaction: "Cr-survival < 4% at 24 h 3 units Vel-positive blood transfused: no untoward response	68	
Anti-Vel	4+	S units ver-positive bood transitised; no untoward response Nine pregnancies, five miscarriages, three live-born infants requiring exchange transfusion	49	
Anti-Jk*	2+	Delayed haemolytic transfusion reaction:		
		HCT: only Jk(a-b+) blood transfusions tolerated	45	
Anti-Jk ^b Anti-Co*	1+	Jkb-positive blood transfused: no untoward response Developed during pregnancy: amniocentesis showed	0	
Anti-Co*	2+	Developed during pregnancy; amniocentesis showed ΔOD _{450nm} = 0-061, Zone 2; caused mild HDN	20\$.5	
† Norma ‡ PRBC § PRBC * Using : less conclu	I PRBC : values wo ratues wo autologos sive (Alp	bulln test using anti-lgG. c 2. re higher when using autologous monocyte-macrophages. re higher twhen using sensitized homozygous antigen positive as monocyte-macrophages: results with allogeneic monocyte- rein or (al. 1983). positive resction.		

MMA useful for drug-induced clinical significance

American Journal of Hematology 18:213-219 (1985)

Extravascular Hemolysis Following the Administration of Cefamandole

Donald R. Branch, Lee R. Berkowitz, Robert L. Becker, Judy Robinson, Marsha Martin, Michael T. Gallagher, and Lawrence D. Petz

Department of Clinical and Experimental Immunology, City of Hope National Medical Center, Duarte, California (D.R.B., M.T.G., L.D.P.), North Carolina Memorial Hospital, Chapel Hill (R. B., R.L.B., M.M.), and The American Red Cross Blood Services, Carolina Region, Charlotte, North Carolina (J.R.)

Canadian Biod Services II

Monocyte- macrophage	red cells	Mo untreated sensitized ent's serum	Using ce coated sensiti	phage interaction famandole- red cells zed with al serum	Using cer coated sensiti	famandole- red cells zed with 's serum
source ^c	AGT ^a	PRBC ^b	AGT	PRBC	AGT	PRBC
Normal 1 Normal 2	0	0	0	0	3+ 3+	17 31
^a Antiglobulin tes ^b Phagocytic inde Normal PRBC ≤ ^c Monocyte-macro control red blood	ex, ie, the aver 2 [10]. ophage function	age number of	phagocytosed	RBC per 100		






- Gallagher MT, Beatty BG, Beatty JD, Mison AP, BRANCH DR. The effect of pretreatment with liposomes on <u>in vitro</u> phagocytosis of sensitized red blood cells by human macrophages. Fed. Proc. 44:1703, 1985
- Shulman IA, Thompson JC, Nelson JM, Vengelen-Tyler V, BRANCH DR. . Autoanti-Gerbich causing severe autoimmune hemolytic anemia. Transfusion 25:447, 1985
- BRANCH DR, Branch CA, Shulman IA, Nitsun M, Mison AP, Gallagher MT. Participation of cellular thiol/disulfide groups in Fc-receptor (FcR) mediated attachment and phagocytosis of IgG-coated target red cells. Fed. Proc. 45:1110, 1986. 45:1110, 1980. Canadian Blood Services In R's in you to give

oui	Results using	-comp	Its of MMA where good lete correlation with clinic ocyte-macrophage phagocytosis assay with alloant w clinical significance or insignificance	ical findings	
	Antibody specificity	IAT*	Documented clinical significance or insignificance	Phagocytic index [†]	
	Anti-M	3+	Significant (Alperin et al, 1983)	4	
	Anti-M	21+	Significant, caused HDN (Cohen, 1985)	61	
	Anti-Ge	2+	Insignificant (Branch et al, 1984)	0	
	Anti-Ge	2+	Insignificant (Branch et al, 1984)	1	
	Anti-Ge	4+	Significant (Branch et al, 1984)	68	
	Anti-Ge‡	21+	Significant (Shulman et al, 1985)	73	
	Anti-Vel	Micro§	Insignificant (Branch et al. 1984)	0	
	Anti-Vel	4+	Significant (Branch et al, 1984)	49	
	Anti-Lan	21+	Significant (Judd et al. 1984)	5	
	Anti-Co*	2+	Significant (Branch et al. 1984)	20	
	Anti-D	21+	Insignificant: anti-D present in i.v. gammaglobulin: 1 litre infused; patient became DAT+ (2+); no clinical evidence of haemolysis (Judd, 1983)	0	
	Anti-Jk*	2+	Significant (Branch et al. 1984)	4	
	Anti-jk*	31+	Significant: caused DHTR: failing Hct 40-7-24-5%); increased bilirubin, LDH; Hct stable after infusion of Ik's nex RBC	26	
	Anti-Jk ^b	1+	Insignificant (Branch et al. 1984)	0	
	Anti-P	3+	Significant (Shirey et al, 1984)	14	
	Anti-Yt*	23+	Insignificant: no HDN (Cohen, 1985)	0	
	Anti-Yt*	Micro	Insignificant: hacmodialysis patient: Hct stable: ⁵¹ Cr T ₁ = 21 d (Garratty et al. 1985)	0	




"Our current experience, although still limited, is encouraging. Thus far, we have correlated 100% using our in vitro monocytemacrophage phagocytosis assay system with the in vivo clinical significance or insignificance of 17 antibodies (four anti-Ge; two each anti-M, -Vel and -Jka; and one each anti-Lan, -Coa, Jkb, -P, -Yta and -Ytb). These results suggest that use of an optimal monocyte-macrophage phagocytosis assay system can accurately reflect the clinical relevance of a given antibody-containing serum in vitro..." Branch DR, Gallahger MT. Br J Haematol. 1986 Apr;62(4):783-5




Results of nor Monocyte-	mal, matern Target red	al, and infant mono	cyte-macroph:	age interaction wi	th sensitized	red cells		
macrophages	control re-	d cells ²		Rh phenot	ypes ³	Anti-D tite	r: 2048	
	high	medium	low	R2R2	R1R1	R ₁ r	R1r'4	rr
Normal Maternal Infant	124 105 47	43 52 17	12 4 4	111 100 44	68 NT NT	44 70 24	11 NT NT	0 0 0
All sensitiz Group O, H Group O re	ed target red R1R2 target r ed cells of va	rious Rh phenotype	positive using with high, med having decrea	; IAT. ium, and low leve asing Rh ₀ (D) anti	ls of comme	Not tested. rcial, single-lot anti-I sity sensitized with n with group A1, Rh-ne	naternal anti-D.	remove





Results of normal cord blood monocyte-macrophage interaction with sensitized red cells						
Cord blood	Control tar	Control target red cells ¹				
monocyte- macrophages	high	medium	low			
1	2.3	3.1	2.9			
2	1.5	0.6	0.4			
3	1.5	2.4	1.6			
4	1.7	1.9	1.3			
5	1.8	2.1	1.0			
(PRBC) to norr ¹ Group O,	mal control PRBC. R1R2 target red ce	o of cord blood phagoo lls were sensitized cial, single-lot anti-D	with high			









































- 1989 Nance et al. showed in 16 women that MMA was more predictive than amniotic fluid analysis in HDFN requiring transfusion
 Am J Clin Pathol 1989;92(1):89-92
- 2004 Arndt and Garratty found with 46 patients that the MMA was 100% accurate in predicting a non-significant antibody Transfusion 2004;44(9):1273-81

Canadian Blood Services it's in you to give







Summary

- MMA use going on 4 decades
- Early and subsequent work showed efficacy of MMA to accurately predict *in vivo* antibody clinical significance or insignificance
- Not many reference laboratories using MMA more should set it up
- MMA useful for:

 - Deciding on clinical significance of autoantibodies irrespective of strength of DAT

 - Deciding on clinical significance of red cell alloantibodies

 - Selection of blood for transfusion to individuals having antibodies to high frequency antigens

nadian Blood Ser it's in you to give

- antigens Deciding on clinical significance of drug-related antik Investigation of mononuclear phagocyte function Resolving problems where suspected clinically significant antibodi Investigation of hemolysis where serologic findings are negative Identification of phagocytosis inhibitors

